RT Journal Article
SR Electronic
T1 A dual-mode targeted Nanopore sequencing assay for comprehensive <em>SMN1</em> and <em>SMN2</em> variant analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.22.24303180
DO 10.1101/2024.02.22.24303180
A1 Hall, Brad
A1 Alyafei, Sawsan
A1 Ramaswamy, Sathishkumar
A1 Sinha, Shruti
A1 El Naofal, Maha
A1 Rabea, Fatma
A1 Killinger, Bryan J.
A1 Latham, Gary J.
A1 Tayoun, Ahmad Abou
YR 2024
UL http://medrxiv.org/content/early/2024/02/23/2024.02.22.24303180.abstract
AB Background Spinal Muscular Atrophy (SMA) is one of the most common recessive disorders for which several life-saving treatment options are currently available. It is essential to establish universal SMA screening and diagnostic programs using scalable, cost-effective and accessible platforms to accurately identify all variation types, which is complicated by homologous SMN1 and SMN2 genes.Methods We developed a dual-mode PCR-based target enrichment that generates 2.7 to 11.2 kb amplicons spanning SMN1 and SMN2 genes for any-length nanopore sequencing. We trained a variant calling model that utilizes paralog-specific sequences and read-depth data to accurately detect sequence and copy number variants specific to each gene.Results We present results from the development, optimization, and external evaluation of this assay using over 750 samples, including cell lines, residual presumed normal blood donors, and patients with known SMN1 and SMN2 genotypes. The assay detects SNVs, indels, and CNVs with &gt;98% accuracy across all sample sets, with a highly dynamic throughput range, relatively fast turnaround time, and limited hands-on-time. Together with the modest capital investment and consumable costs per sample, this assay can help increase access to SMA testing in low- and middle-income settings.Conclusion We describe a PCR/Nanopore sequencing assay and a customized analysis pipeline for the comprehensive and accurate detection of variation at the SMA locus and demonstrate its scalability, cost-effectiveness, and potential for the universal implementation of SMA screening and diagnostic programs.Human Genes SMN1 survival of motor neuron 1, telomeric HGNC:11117 SMN2 survival of motor neuron 2, centromeric HGNC:11118 CFTR CF transmembrane conductance regulator HGNC:1884Competing Interest StatementBH, BK, and GL are employees of Bio-Techne with stock and stock options in this company.Funding StatementThis study received funding support from Asuragen and Oxford Nanopore Technologies in the form of reagents and consumables.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Dubai Health Authority Research Ethics Committee gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscriptSMASpinal Muscular AtrophySNVsSingle nucleotide variants Indels, Insertions and deletionsCNVsCopy number variantsNGSNext generation sequencingUSUnited StatesFDAFood and Drug AdministrationHRMHigh-resolution meltMLPAMultiplex ligation-dependent probe amplificationONTOxford Nanopore TechnologiesPCRPolymerase chain reactiongDNAGenomic DNANHGRINational Human Genome Research InstituteNIGMSNational Institute of General Medical SciencesddPCRdroplet digital PCRCECapillary electrophoresisQCQuality control